By using, you agree to our terms and use of cookies to enhance your experience.

Unclear results from study exploring aspirin in diabetes

By Editor
5th September 2018

Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding, according to a new study.

The researchers say the findings mean the “balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear”.

The trial involved assigning 15,480 people with diabetes and no previous evidence of cardiovascular disease into different groups. One group was given 100 mg daily doses of aspirin and the other group received a placebo.

The primary efficacy outcome was the first serious vascular event, for example myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage.

The primary safety outcome was the first major bleeding event, for example intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer.

During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01).

In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding.

There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned.

The researchers concluded: “Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard.”

To read the study, click here.

Comments (0)

Register an account or login to comment